Randall Moreadith Sells 6,500 Shares of Serina Therapeutics (NYSEAMERICAN:SER) Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) insider Randall Moreadith sold 6,500 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $2.86, for a total transaction of $18,590.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Randall Moreadith also recently made the following trade(s):

• On Thursday, March 19th, Randall Moreadith sold 39,000 shares of Serina Therapeutics stock. The shares were sold at an average price of $2.50, for a total transaction of $97,500.00.
• On Monday, February 2nd, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.03, for a total transaction of $19,695.00.
• On Wednesday, January 28th, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.57, for a total transaction of $23,205.00.
• On Thursday, January 22nd, Randall Moreadith sold 2,500 shares of Serina Therapeutics stock. The stock was sold at an average price of $2.95, for a total transaction of $7,375.00.
• On Wednesday, January 21st, Randall Moreadith sold 2,000 shares of Serina Therapeutics stock. The stock was sold at an average price of $3.00, for a total transaction of $6,000.00.

Serina Therapeutics Price Performance

NYSEAMERICAN:SER opened at $2.61 on Friday. Serina Therapeutics, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $7.92. The business’s 50 day moving average is $2.14. The stock has a market cap of $28.16 million, a PE ratio of -1.37 and a beta of 1.25.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its earnings results on Wednesday, March 25th. The company reported ($0.31) earnings per share (EPS) for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.